Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model.
Daptomycin (LY 146032), a new lipopeptide antimicrobial agent with activity against gram-positive bacteria, was compared to vancomycin in the treatment of staphylococcal bacteremia in a murine model. Two hundred and ninety-nine mice were inoculated with 1 x 10(8) bacteria by the tail vein, and treatment was begun 3 days later. Two dosage regimens of each drug were used: 10 mg/kg and 5 mg/kg administered every 12 h for 14 days. A control group received no therapy. Survival was determined 31 days after inoculation. There was no significant difference in survival in any of the four treatment groups. The survival in all treatment groups was significantly greater than in the control group. Serum levels of daptomycin remained longer in the therapeutic range than serum levels of vancomycin. In the murine model of staphylococcal disease, daptomycin treatment was as effective as treatment with vancomycin.
Smith
K
K
Division of Infectious Diseases, University of Alabama School of Medicine, Birmingham.
Cobbs
G
G
Dill
R
R
Lyon
D
D
Graves
A
A
Avent
K
K
D000818:Animals; D017576:Daptomycin; D005260:Female; D051379:Mice; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000097:blood / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology; D014640:Vancomycin / Q000097:blood / Q000627:therapeutic use*
D010455:Peptides; D014640:Vancomycin; D017576:Daptomycin